Leave R&D tax credits alone, warns Medicines Australia
This article was originally published in Scrip
Winding back Australia's R&D tax credit system could cause some companies to stop bringing R&D investment dollars to Australia, warned Dr Brendan Shaw, chief executive of Medicines Australia, in a statement today. His comments come in response to Australian media reports that the government may change the tax credit system in the forthcoming federal budget.
You may also be interested in...
WTO member states including the EU, the US and the UK argue that waiving certain IP rights is unnecessary for enhancing responses to the Covid-19 pandemic.
Insurers argue that better use of real world data and multiple pricing assessments could help lower drug prices in Germany.
To keep investors happy, companies will have to start showing that their high-priced advanced therapies offset costs elsewhere in the health care system.